[go: up one dir, main page]

UY38707A - Nuevos antagonistas cíclicos del receptor b2 de bradiquinina - Google Patents

Nuevos antagonistas cíclicos del receptor b2 de bradiquinina

Info

Publication number
UY38707A
UY38707A UY0001038707A UY38707A UY38707A UY 38707 A UY38707 A UY 38707A UY 0001038707 A UY0001038707 A UY 0001038707A UY 38707 A UY38707 A UY 38707A UY 38707 A UY38707 A UY 38707A
Authority
UY
Uruguay
Prior art keywords
receptor
bradiquinin
new cyclic
compound
cyclic antagonists
Prior art date
Application number
UY0001038707A
Other languages
English (en)
Inventor
Christoph Gibson
Joern Saupe
Ambrosi Horst-Dieter
Ole Haustedt Lars
Original Assignee
Pharvaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris Gmbh filed Critical Pharvaris Gmbh
Publication of UY38707A publication Critical patent/UY38707A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un compuesto de acuerdo con la formula general (I), que actúa como un antagonista del receptor de bradiquinina (BK) B2; a una composición farmacéutica que contiene uno o más compuestos de la invención; a una preparación de combinación que contiene al menos un compuesto de la invención y al menos otro principio farmacéuticamente activo adicional; y a los usos de dicho(s) compuesto(s), incluido el uso como medicamento.
UY0001038707A 2019-05-23 2020-05-21 Nuevos antagonistas cíclicos del receptor b2 de bradiquinina UY38707A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19176229 2019-05-23

Publications (1)

Publication Number Publication Date
UY38707A true UY38707A (es) 2020-12-31

Family

ID=66668714

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038707A UY38707A (es) 2019-05-23 2020-05-21 Nuevos antagonistas cíclicos del receptor b2 de bradiquinina

Country Status (13)

Country Link
US (1) US12391681B2 (es)
EP (1) EP3956326B1 (es)
JP (1) JP7459235B2 (es)
CN (1) CN113906020B (es)
AR (1) AR118983A1 (es)
AU (1) AU2020277697B2 (es)
CA (1) CA3139228A1 (es)
ES (1) ES2958457T3 (es)
MX (1) MX2021014287A (es)
PL (1) PL3956326T3 (es)
TW (1) TWI827846B (es)
UY (1) UY38707A (es)
WO (1) WO2020234480A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38706A (es) * 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
US20250228781A1 (en) * 2022-03-25 2025-07-17 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
CN119219577A (zh) * 2024-09-25 2024-12-31 浙江工业大学 一种(5s,6r)-5,6-环氧-2-十七碳炔-1-醇的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
WO1996013485A1 (en) 1994-10-27 1996-05-09 Fujisawa Pharmaceutical Co., Ltd. Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19612067A1 (de) 1996-03-27 1997-10-02 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
AU6422098A (en) * 1997-03-24 1998-10-20 Kyowa Hakko Kogyo Co. Ltd. Benzene derivatives
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
WO1999064039A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Bradykinin antagonists
BR9914785A (pt) 1998-10-21 2001-07-03 Fujisawa Pharmaceutical Co Formavìtrea de 8-[3-[n-[(e)-3-(6-acetamidopiridin-3-il) acriloilglicil]-n-metilamino]-2,6-diclorobenziloxi)-2- metilquinolina, processo para sua preparação, composição farmacêutica compreendendo a mesma, agente de prevenção, seu métodos e uso
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
CA2369544A1 (en) * 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives:selective modulators of bradykinin b2 receptors
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2001056995A1 (en) 2000-01-18 2001-08-09 Nuerogen Corporation Substituted imidazoles as selective modulators of bradykinin b2 receptors
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
US6958349B2 (en) 2002-04-10 2005-10-25 Ortho-Mcneil Pharmaceuticals, Inc. Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1741444A1 (en) 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
TWI407960B (zh) * 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
RU2015138443A (ru) * 2013-03-14 2017-04-20 Шир Хьюман Дженетик Терапис, Инк. Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2
DK3713928T3 (da) 2017-11-24 2022-04-04 Pharvaris Netherlands B V Hidtil ukendte bradykinin-b2-receptorantagonister
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina

Also Published As

Publication number Publication date
TW202110833A (zh) 2021-03-16
CN113906020B (zh) 2024-03-12
JP2022533487A (ja) 2022-07-22
TWI827846B (zh) 2024-01-01
CN113906020A (zh) 2022-01-07
EP3956326C0 (en) 2023-06-28
PL3956326T3 (pl) 2024-01-22
EP3956326A1 (en) 2022-02-23
MX2021014287A (es) 2022-01-06
US12391681B2 (en) 2025-08-19
AR118983A1 (es) 2021-11-17
AU2020277697A1 (en) 2021-11-18
JP7459235B2 (ja) 2024-04-01
CA3139228A1 (en) 2020-11-26
US20220289730A1 (en) 2022-09-15
AU2020277697B2 (en) 2023-08-24
WO2020234480A1 (en) 2020-11-26
EP3956326B1 (en) 2023-06-28
ES2958457T3 (es) 2024-02-08

Similar Documents

Publication Publication Date Title
UY37981A (es) Novedosos antagonistas del receptor b2 de bradiquinina
UY38707A (es) Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2018002326A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
CL2022001439A1 (es) Combinación de antagonista del receptor lpa1 de azetidina con pirfenidona y, o nintedanib.
CO2017011411A2 (es) Derivados de ciclohexano sustituido con amido
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
CO2021006482A2 (es) Ureas cíclicas
MX375978B (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
PE20200740A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
CL2018000529A1 (es) Compuestos heteroarilo y su uso como fármacos terapéuticos.
CO2023005973A2 (es) Profármacos de glp-1 y usos de los mismos
MX2021015654A (es) Antagonista del receptor 2 de prostaglandina e2 (ep2).
MX2019014445A (es) Preparacion hidratante topica.
CL2009001016A1 (es) Preparacion farmaceutica solida con liberacion retardada que comprende: a) un ingrediente farmaceuticamente activo, b) 15 a 40% en peso de una mezcla de polivinilpirrolidona y/o un derivado de polivinilpirrolidona y c) al menos un diluyente.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
CL2020001817A1 (es) Moduladores del receptor c5a
CL2020002188A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.
MX2025011781A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
BRPI0808377B8 (pt) composto, composição e uso de um composto